Results 241 to 250 of about 107,975 (358)

Health Policy Newsletter March 2007 Vol. 20, No. 1 [PDF]

, 2008

core   +1 more source

Relationship between medication use and non‐attendance (missed appointment) from primary care visits among people with type 2 diabetes: The Japan Diabetes Outcome Intervention Trial‐2 Large‐Scale Trial 006 (J‐DOIT2‐LT006)

Journal of Diabetes Investigation, EarlyView.
Taking oral medications might prevent non‐attendance, and multifaceted interventions might prevent non‐attendance, regardless of medication use. However, no significant difference was observed in insulin usage. ABSTRACT Aims/Introduction To clarify the relationship between medication use and primary care visit non‐attendance (missed appointment) among ...
Yusuke Hikima, Ryotaro Bouchi, Yasuaki Hayashino, Atsushi Goto, Hikari Suzuki, Katsuya Yamazaki, Kazuo Izumi, Masaomi Nangaku, Mitsuhiko Noda, J‐DOIT2 Study Group   +9 more
wiley   +1 more source

Polytropic Influence of TRIB3 rs2295490 Genetic Polymorphism on Response to Antihypertensive Agents in Patients With Essential Hypertension. [PDF]

Front Pharmacol, 2019
Zhou J, He F, Sun B, Liu R, Gao Y, Ren H, Shu Y, Chen X, Liu Z, Zhou H, Deng S, Xu H, Li J, Xu L, Zhang W.   +14 more
europepmc   +1 more source

Soy protein: The next antihypertensive agent? [PDF]

, 2005
Ana M. Saldarriaga Cartagena
openalex   +1 more source

Retrospective analysis of influences of sacubitril/valsartan in patients with diabetes with poorly controlled blood pressure in Japan

Journal of Diabetes Investigation, EarlyView.
Sacubitoril/valsartan vs thiazide in patients with diabetes. ABSTRACT Aims Achieving optimal blood pressure control remains challenging, particularly for patients with diabetes. This post‐hoc study compared the efficacy and safety of switching to sacubitril/valsartan vs adding thiazide diuretics in this population.
Shun Ito, Kazuo Kobayashi, Mari Sotozawa, Kyoji Chiba, Keiichi Chin, Hideo Shimura, Toshinao Tsuge, Hiroyuki Sakai, Takayuki Furuki, Atsushi Matsuzaki, Shinichi Nakajima, Nobukazu Takada, Hareaki Yamamoto, Hiroshi Takeda, Hiromichi Wakui, Takamasa Iwasawa, Togo Aoyama, Kouichi Tamura, Masao Toyoda, Akira Kanamori   +19 more
wiley   +1 more source

Long‐term safety and efficacy of imeglimin in Japanese individuals with type 2 diabetes and chronic kidney disease: A 52‐week postmarketing clinical study (TWINKLE)

Journal of Diabetes Investigation, EarlyView.
This study confirmed the long‐term safety and efficacy of an adjusted‐dose regimen of imeglimin in Japanese participants with type 2 diabetes and grade (G) 3b–5 chronic kidney disease (CKD). Adverse events occurred in 41 participants (68.3%), with no increase in the incidence, type, and severity of AEs between CKD cohorts.
Tetsuya Babazono, Takeshi Osonoi, Hideki Okamoto, Yukiko Onishi, Shinya Nakamoto, Masayuki Kashima, Daiji Kawanami, Eitaro Nakashima, Kei Watabe, Noriko Nunami, Katsuhiko Hagi   +10 more
wiley   +1 more source

Between-country variation in the utilization of antihypertensive agents: guidelines and clinical practice [PDF]

, 2006
Pieter Stolk, Boris L.G. Van Wijk, Hubert G. M. Leufkens, Eibert R. Heerdink   +3 more
openalex   +1 more source

The Influence of Microneedles on the Percutaneous Penetration of Selected Antihypertensive Agents: Diltiazem Hydrochloride and Perindopril Erbumine. [PDF]

Curr Drug Deliv, 2018
Luu E, Ita KB, Morra MJ, Popova IE.
europepmc   +1 more source

Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Background and Aim Atezolizumab plus bevacizumab is used as a first‐line treatment for unresectable hepatocellular carcinoma (uHCC). However, the relationship between its adverse events (AEs) and treatment efficacy remains unclear. In this study, we aimed to clarify this association.
Kazuki Maesaka, Hayato Hikita, Machiko Kai, Yuki Tahata, Kumiko Shirai, Akira Doi, Kazuhiro Murai, Yoshinobu Saito, Ryoko Yamada, Takahiro Kodama, Kazuyoshi Ohkawa, Masanori Miyazaki, Hisashi Ishida, Kengo Matsumoto, Yasutoshi Nozaki, Takayuki Yakushijin, Ryotaro Sakamori, Nobuyuki Tatsumi, Sadaharu Iio, Takatoshi Nawa, Naruyasu Kakita, Masanori Nakahara, Atsushi Hosui, Takeo Usui, Kazuho Imanaka, Yoshinori Doi, Mitsuru Sakakibara, Yuichi Yoshida, Tomohide Tatsumi, Tetsuo Takehara   +29 more
wiley   +1 more source

SCORE2‐Older Persons (SCORE2‐OP): Validation and Added Value of Excessive Daytime Sleepiness in a French Cohort

Journal of the American Geriatrics Society, EarlyView.
External validation of SCORE2‐OP in older French adults and incremental value of excessive daytime sleepiness for cardiovascular risk prediction: SCORE2‐OP showed moderate discrimination and overestimated risk by 25%. Adding EDS did not improve overall model performance but enhanced classification in low‐ and intermediate‐risk groups.
Tahiana Andriambelosoa, Clémence Cavaillès, Jean‐Philippe Empana, Thibault Mura, Catherine Helmer, Yves Dauvilliers, Isabelle Jaussent   +6 more
wiley   +1 more source